These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 36986790)
1. Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma. Cruz N; Herculano-Carvalho M; Roque D; Faria CC; Cascão R; Ferreira HA; Reis CP; Matela N Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986790 [TBL] [Abstract][Full Text] [Related]
2. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316 [TBL] [Abstract][Full Text] [Related]
3. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985 [TBL] [Abstract][Full Text] [Related]
4. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. Carter TC; Medina-Flores R; Lawler BE Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753 [TBL] [Abstract][Full Text] [Related]
5. Nanotechnology for Treatment of Glioblastoma Multiforme. Michael JS; Lee BS; Zhang M; Yu JS J Transl Int Med; 2018 Sep; 6(3):128-133. PubMed ID: 30425948 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. Fabian D; Guillermo Prieto Eibl MDP; Alnahhas I; Sebastian N; Giglio P; Puduvalli V; Gonzalez J; Palmer JD Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30717372 [TBL] [Abstract][Full Text] [Related]
8. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983 [TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Yalamarty SSK; Filipczak N; Li X; Subhan MA; Parveen F; Ataide JA; Rajmalani BA; Torchilin VP Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046777 [TBL] [Abstract][Full Text] [Related]
11. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047 [TBL] [Abstract][Full Text] [Related]
12. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system. Turner SG; Gergel T; Wu H; Lacroix M; Toms SA World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522 [TBL] [Abstract][Full Text] [Related]
13. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151 [TBL] [Abstract][Full Text] [Related]
15. A narrative review of research progress on drug therapies for glioblastoma multiforme. Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258 [TBL] [Abstract][Full Text] [Related]
16. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. Yasaswi PS; Shetty K; Yadav KS J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126 [TBL] [Abstract][Full Text] [Related]
18. Time trends in glioblastoma multiforme survival: the role of temozolomide. Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259 [TBL] [Abstract][Full Text] [Related]
19. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023 [TBL] [Abstract][Full Text] [Related]
20. Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme. Mirza FA; Shamim MS J Pak Med Assoc; 2018 Oct; 68(10):1543-1545. PubMed ID: 30317361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]